US · Healthcare · Biotechnology
EPS came in at -0.05 against a street estimate of -0.03 — a miss of 66.7%.
Analysts rate MiMedx Group Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $7.40.
| Fund | Stake |
|---|---|
| Essex Woodlands Health Ventures | 19.32% |
| BlackRock Inc | 8.33% |
| Nantahala Capital Management, LLC | 6.53% |
| Trigran Investments Inc | 4.92% |
| State Street Corp | 3.82% |
| Vanguard Capital Management, LLC | 3.55% |
| Paradigm Capital Management, Inc. | 2.79% |
| Geode Capital Management, LLC | 2.15% |
| Document | Date |
|---|---|
| Company announcement · Q4 2026 HEADLINE NUMBERS • On October 15, 2026, MiMedx Group, Inc. and Sanara MedTech Inc. each received a “Second Request” for additional information and do | 2026-10-16 |
| Quarterly report · Q2 2026 MIMEDX GROUP, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales Q2 2026: $64.4 million (down 34.7% vs. Q2 2025: $98.6 million) • Net sales H1 | 2026-07-29 |
| Results announced · Q3 2026 MIMEDX GROUP, INC. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $64 million (down 35% vs. $99 million in Q2 2025) • Six-Month 20 | 2026-07-29 |
| Material agreement · Q3 2026 MIMEDX GROUP, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Merger Consideration per Sanara Share: $33.00 cash + 0.4735 MiMedx shares (stock valued at | 2026-07-29 |
| Charter / bylaws change · Q2 2026 MIMEDX GROUP, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting Date: June 10, 2026 • Shareholder Participation: 125,360,965 shares represen | 2026-06-16 |
| Quarterly report · Q1 2026 MIMEDX GROUP, INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Net sales Q1 2026: $58.991 million (down 33.2% from $88.205 million in Q1 2025) • Net loss Q | 2026-04-29 |
| Proxy statement · Q4 2025 MIMEDX GROUP, INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect seven directors: Joseph H. Capper, James L. Bi | 2026-04-29 |
| Results announced · Q2 2026 MIMEDX INVESTOR SUMMARY – APRIL 2026 HEADLINE NUMBERS • LTM Net Sales (Q1 2026): $388 million • LTM Adjusted EBITDA: $148 million (38% margin) • Net | 2026-04-29 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MiMedx Group Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.